Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background— Chronic kidney disease (CKD) is an established risk factor for poor outcomes in heart failure (HF). Whether proteinuria provides additional prognostic information is not known. Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness. Methods and Results— In the Valsartan in Heart Failure Trial (Val-HeFT), 5010 patients with class II, III, or IV heart failure were randomly assigned to receive valsartan or placebo. The 2 primary outcomes were death and first morbid event, defined as death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilator drugs for 4 hours or more without hospitalization. The study cohort was divided into subgroups according to the presence of CKD (estimated glomerular filtration rate <60 mL · min −1 · 1.73 m −2 ) and proteinuria (positive dipstick). Multivariable Cox proportional hazards regression models were used to examine the relationships between study outcomes and proteinuria, including its interaction with CKD. The interaction between valsartan and CKD was also tested. The effect of valsartan on estimated glomerular filtration rate was estimated by generalized linear models, including tests of interactions between treatment and CKD. At baseline, CKD was found in 58% and dipstick-positive proteinuria in 8% of patients. Dipstick-positive proteinuria was independently associated with mortality (hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.01 to 1.62, P =0.05) and first morbid event (HR 1.28, 95% CI 1.06 to 1.55, P =0.01). The increased risk of death associated with dipstick-positive proteinuria was similar for those with and without CKD (HR 1.26, 95% CI 0.96 to 1.66 versus HR 1.37, 95% CI 0.83 to 2.26; P =0.94), as was the hazard for first morbid event (HR 1.26, 95% CI 1.01 to 1.57 versus HR 1.42, 95% CI 0.98 to 2.07; P =0.71). Valsartan reduced estimated glomerular filtration rate compared with placebo to a similar extent ( P =0.52) in the subgroups with CKD (mean reduction −3.6 mL · min −1 · 1.73 m −2 ) and without CKD (mean reduction −4.0 mL · min −1 · 1.73 m −2 ) and by −3.8 mL · min −1 · 1.73 m −2 in both groups combined. The beneficial effect of valsartan on first morbid events was similar in those with and without CKD (HR 0.86, 95% CI 0.74 to 0.99 versus HR 0.91, 95% CI 0.73 to 1.12; P =0.23) and was significant in the subgroup with CKD. The effect of valsartan on mortality did not differ in patients with and without CKD (HR 1.01, 95% CI 0.85 to 1.20 versus HR 0.91, 95% CI 0.69 to 1.25; P =0.08). Conclusions— CKD was common and dipstick-positive proteinuria was infrequent in this sample of patients with HF. After controlling for other risk factors, including CKD, the relatively small subgroup with dipstick-positive proteinuria did have worse outcomes. Valsartan reduced the estimated glomerular filtration rate by the same amount in patients with and without CKD and reduced the risk of the first morbid event in patients with CKD, which suggests its beneficial effects in patients with HF and CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationGerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 3×
“Diabetes mellitus 381 (20) 685 (26) 40 (35) 156 (54) 0.”
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
Hillege, H. L., Nitsch, D., Pfeffer, M. A., Swedberg, K., McMurray, J. J. V., Yusuf, S., Granger, C. B., Michelson, E. L., Östergren, J., Cornel, J. H., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.580506 · Cited by 945
Calculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
Research works printed but not linked: 34
- 10.1161/circulationaha.107.188511 · DOI · Paper page
- 10.1161/circ.102.2.203 · doi:10.1161/circ.102.2.203
- 10.1097/01.ASN.0000135121.81744.75 · DOI
- 10.1016/S0735-1097(99)00608-7 · DOI · Paper page
- 10.1681/ASN.2005030270 · DOI
- 10.1016/j.ahj.2004.02.007 · doi:10.1016/j.ahj.2004.02.007
- 10.1016/j.amjcard.2006.08.042 · DOI · Paper page
- 10.1161/01.cir.0000116764.53225.a9 · DOI · Paper page
- 10.1016/j.jacc.2004.06.072 · DOI · Paper page
- 10.1097/01.ASN.0000018409.45834.FA · DOI · Paper page
- 10.1016/j.ahj.2007.03.017 · DOI
- 10.1001/archinte.167.18.1930 · DOI · Paper page
- 10.1161/01.cir.0000149806.01354.bf · DOI · Paper page
- 10.1016/j.cardfail.2005.05.007 · DOI
- Ellekilde G, Holm J, von Eyben FE, Hemmingsen L. Above-normal urinary excretion of albumin and retinol-binding protein in chronic heart failure. Clin Chem. 1992; 38: 593–594.
- 10.1159/000166727 · DOI
- 10.1136/bmj.38814.566019.2F · DOI · Paper page
- 10.1681/ASN.V133745 · DOI · Paper page
- 10.1038/ki.1996.481 · DOI · Paper page
- 10.1046/j.1523-1755.1998.00874.x · DOI · Paper page
- 10.1111/j.1523-1755.2004.00653.x · DOI · Paper page
- 10.1161/01.cir.0000139860.33974.28 · DOI · Paper page
- Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. Nov 2004: S50–S55.
- 10.7326/0003-4819-139-11-200312020-00008 · DOI · Paper page
- 10.7326/0003-4819-148-1-200801010-00190 · DOI · Paper page
- 10.1016/S0140-6736(08)61236-2 · DOI · Paper page
- 10.7326/0003-4819-130-6-199903160-00002 · DOI · Paper page
- 10.1053/ajkd.2002.29865 · DOI · Paper page
- 10.1093/aje/kwn033 · DOI · Paper page
- 10.1681/ASN.2006050517 · DOI · Paper page
- 10.1161/circulationaha.107.723270 · DOI · Paper page
- 10.1111/j.1464-410X.1989.tb05166.x · DOI
- 10.1172/JCI103127 · DOI · Paper page
- 10.1056/NEJM198204293061706 · doi:10.1056/nejm198204293061706
Cited by
Inker, L. A., Astor, B. C., Fox, C. H., Isakova, T., Lash, J. P., Peralta, C. A., Kurella Tamura, M., & Feldman, H. I. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.416 · Cited by 1,779
Rangaswami, J., Bhalla, V., Blair, J. E. A., Chang, T. I., Costa, S., Lentine, K. L., Lerma, E. V., Mezue, K., Molitch, M., Mullens, W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000664 · Cited by 1,409
Damman, K., Valente, M. A. E., Voors, A. A., O'Connor, C. M., van Veldhuisen, D. J., & Hillege, H. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht386 · Cited by 1,125
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
McMurray, J. J. V., Abraham, W. T., Dickstein, K., Køber, L., Massie, B. M., & Krum, H. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs033 · Cited by 1,096
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Metadata
- Authors
- Anand, I. S., Bishu, K., Rector, T. S., Ishani, A., Kuskowski, M. A., & Cohn, J. N.
- Venue
- Circulation
- Published
- 2009-10-20
- Volume
- 120
- Issue
- 16
- Pages
- 1577-1584
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2104402487
- Cited by
- 145
- References
- 4
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure. https://app.cochat.ai/papers/10.1161/circulationaha.109.853648
- The paper
- Anand, I. S., Bishu, K., Rector, T. S., Ishani, A., Kuskowski, M. A., & Cohn, J. N. (2009). Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure. Circulation. https://doi.org/10.1161/circulationaha.109.853648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.